Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TOCILIZUMAB Cause Irritable bowel syndrome? 3,854 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 3,854 reports of Irritable bowel syndrome have been filed in association with TOCILIZUMAB (Tocilizumab-anoh). This represents 3.9% of all adverse event reports for TOCILIZUMAB.

3,854
Reports of Irritable bowel syndrome with TOCILIZUMAB
3.9%
of all TOCILIZUMAB reports
1,618
Deaths
1,937
Hospitalizations

How Dangerous Is Irritable bowel syndrome From TOCILIZUMAB?

Of the 3,854 reports, 1,618 (42.0%) resulted in death, 1,937 (50.3%) required hospitalization, and 1,627 (42.2%) were considered life-threatening.

Is Irritable bowel syndrome Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TOCILIZUMAB. However, 3,854 reports have been filed with the FAERS database.

What Other Side Effects Does TOCILIZUMAB Cause?

Drug ineffective (32,342) Rheumatoid arthritis (20,652) Pain (18,384) Off label use (18,256) Arthralgia (15,536) Joint swelling (14,831) Fatigue (13,802) Rash (12,327) Drug intolerance (11,952) Contraindicated product administered (11,547)

What Other Drugs Cause Irritable bowel syndrome?

METHOTREXATE (4,155) ABATACEPT (4,069) ADALIMUMAB (3,915) LEFLUNOMIDE (3,897) CERTOLIZUMAB PEGOL (3,740) GOLIMUMAB (3,684) ETANERCEPT (3,419) RITUXIMAB (3,393) ACETAMINOPHEN (3,337) OXYCODONE (3,241)

Which TOCILIZUMAB Alternatives Have Lower Irritable bowel syndrome Risk?

TOCILIZUMAB vs TOCILIZUMAB-AAZG TOCILIZUMAB vs TOCOPHEROL TOCILIZUMAB vs TOFACITINIB TOCILIZUMAB vs TOFERSEN TOCILIZUMAB vs TOLNAFTATE

Related Pages

TOCILIZUMAB Full Profile All Irritable bowel syndrome Reports All Drugs Causing Irritable bowel syndrome TOCILIZUMAB Demographics